The goal of this observational study is to compare the fluctuation patterns of biomarkers (Spirometry, FeNO, IOS) of responders and non-responders in asthma patients who will start treatment with a biologic. The main question it aims to answer is: Can fluctuation patterns of parameters for spirometry, FeNO and IOS before and after starting treatment with biologics in patients with severe asthma be used to predict a successful intervention.
Participants will measure Spirometry, FeNO and IOS twice a day at home for 2 or 3 months starting one month before starting treatment with a biological.

Start Date01 Dec 2023

Sponsor / Collaborator

Academic Medical Center University of Amsterdam

NCT04710134

/ CompletedPhase 4IIT

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy

Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.

Start Date10 Feb 2021

Sponsor / Collaborator

McMaster University

[+1]

NCT04183192

/ CompletedPhase 1IIT

Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 1: Interleukin-5 Antagonists - Mepolizumab and Reslizumab

This study is designed to assess pharmacokinetics and pharmacodynamics of mepolizumab and reslizumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies.
This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (mepolizumab or reslizumab) or placebo.

Start Date17 Feb 2020

Sponsor / Collaborator

US Food & Drug Administration

[+1]

100 Clinical Results associated with Reslizumab

100 Translational Medicine associated with Reslizumab

100 Patents (Medical) associated with Reslizumab

392

Literatures (Medical) associated with Reslizumab

28 Feb 2025·CROATIAN MEDICAL JOURNAL

Effectiveness of biological therapy in severe asthma: a retrospective real-world study.

Article

Author: Štajduhar, Anamarija ; Rnjak, Dina ; Popović-Grle, Sanja ; Safić Stanić, Hana ; Lampalo, Marina

METHODS:

We retrospectively collected data on 74 patients treated with one of four different biologics (omalizumab, mepolizumab, reslizumab, or benralizumab) at the Jordanovac Clinic for Pulmonary Diseases, Zagreb, Croatia for at least two years. The patients were compared in terms of the number of exacerbations, dose of oral corticosteroids (OCS), asthma control test (ACT), forced expiratory volume in 1 second (FEV1), forced vital capacity, fraction of exhaled nitric oxide (FeNO), number of blood eosinophils, and total immunoglobulin E (IgE).

RESULTS:

All treatment outcome measures, except FeNO, significantly improved in the two-year period (P<0.001). The number of acute exacerbations decreased in all groups. Reslizumab-treated patients showed the greatest improvement in ACT score, and the omalizumab-treated patients experienced the least (P=0.018). The benralizumab group showed the greatest reduction in eosinophil number, and the omalizumab group the lowest (P<0.001). The mepolizumab group showed the greatest improvement in FEV1.

CONCLUSION:

Both anti-IgE and anti-IL-5 treatments effectively reduced exacerbation rates, OCS daily needs, and symptom burden. Multiple predictive biomarkers are needed for the best individual monitoring.

26 Feb 2025·Polish Journal of Otolaryngology

Results of personalized biological therapy in patients with chronic rhinosinusitis with nasal polyps and severe uncontrolled bronchial asthma – real-life study

Article

Author: Gawlik, Radoslaw ; Niemiec-Gorska, Aleksandra ; Rymarczyk, Barbara ; Branicka, Olga ; Glȕck, Joanna ; Jura-Szoltys, Edyta ; Rozlucka, Lesia

Introduction: Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequently comorbid diseases caused by type 2 inflammation. The complete etiology of these forms still remains unexplained, which makes causal and fully effective therapeutic management impossible. New therapeutic options using the knowledge of Th2 inflammatory endotype are based on anti-IL5 (mepolizumab, reslizumab), anti-IL5R (benralizumab), anti-IgE (omalizumab), and anti-IL4/IL13 (dupilumab) monoclonal antibodies. Recently, biological therapy has provided a new personalized therapeutic option for patients with CRSw NP.

Aim: The aim of the study was to evaluate the efficacy of mepolizumab, benralizumab, omalizumab, and dupilumab in the reduction of rhinological symptoms in severe asthmatic patients with chronic rhinosinusitis with nasal polyps.

Materials and methods: In 32 (9 male, 18%) patients with CRSwNP and severe bronchial asthma treated with biologics – mepolizumab (19, 59%), omalizumab (5, 15%), benralizumab (6, 19%), and dupilumab (2, 6%) for 6 months, a subjective evaluation of rhinologic symptoms was conducted (TNSS, SNOT, smell evaluation).

Results: In all analyzed groups, 6-month treatment with mepolizumab, omalizumab, and benralizumab resulted in significant improvement in rhinitis symptoms assessed by TNSS and SNOT scales as well as in the sense of smell. Due to the small group of patients treated with dupilumab, statistical analysis in this group was not performed.

Conclusions: Our real-life observation confirmed that biological therapy based on phenotyping enables achieving optimal therapeutic effects for patients with CRSwNP and severe bronchial asthma. Biological therapy should be conducted through a collaborative and multidisciplinary approach.

01 Feb 2025·JOURNAL OF ASTHMA

A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting

Article

Author: Colque-Bayona, Monica ; Laorden, Daniel ; Navarro-Cascales, Tatiana ; Fernandez-Concha, Inés ; Domínguez-Ortega, Javier ; Quirce, Santiago

OBJECTIVE:

This study aimed to compare the clinical characteristics and treatment outcomes of allergic patients (AP) and non-allergic patients (NAP) with severe eosinophilic asthma (SEA) treated with anti-IL5/IL5R biologic agents (mepolizumab, benralizumab, or reslizumab) over one year. Sub-analyses assessed treatment response variations between AP and NAP based on the biological used and compared outcomes among AP with and without fungal allergy.

METHODS:

Observational retrospective analysis. Clinical characteristics, laboratory findings, pulmonary function tests, Asthma Control Test (ACT) scores, oral corticosteroid (OCS) usage, and exacerbation frequency were assessed at the initiation of biological treatment and after one year.

RESULTS:

Sixty-five patients with SEA were included, 41 AP and 24 NAP. 55.4% were treated with mepolizumab, 33.8% with benralizumab, and 10.8% with reslizumab. Before anti-IL5/5R treatment, AP had worse baseline outcomes but there were no differences in pulmonary function. Mean annual exacerbation rate and percentage of patients requiring OCS and dose of prednisone were higher in AP than NAP. AP had significantly higher total IgE values. After one year of treatment, more AP discontinued OCS than NAP (p = 0.025). Both experienced a significant reduction in exacerbation frequency (p = 0.001) and improved respiratory function. 70.7% of AP and 60% of NAP improved ACT ≥3 points. There was no significant difference between AP and NAP using mepolizumab (p = 0.145) or benralizumab (p = 0.174) in reducing OCS.

CONCLUSIONS:

Anti-IL5/IL5R reduced the need for OCS and improved asthma control, regardless of allergic status. Fungal allergy led to lower ACT scores and higher exacerbations than other allergens; both groups improved with anti-IL5/ILR.

News (Medical) associated with Reslizumab

03 Apr 2024

·synapse.patsnap.com

AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma

Asthma is a chronic respiratory disease characterized by chronic inflammation of the airways and reversible airway obstruction. Individuals with asthma have sensitive airways that can narrow when exposed to triggers, leading to difficulties in breathing, wheezing, coughing, and a feeling of chest tightness. Asthma patients experience recurrent episodes of breathing difficulties and wheezing that vary in severity and frequency over time. Globally, as many as 262 million people are affected by asthma, with about 25 million in the United States alone. These patients face the risk of severe exacerbations regardless of the severity of their condition, adherence to treatment, or level of control. It is estimated that there are 136 million exacerbations of asthma annually worldwide. These exacerbations pose a physical threat and emotional impact on many patients and can be fatal. Many patients with asthma symptoms use short-acting β2-adrenergic receptor agonists, such as albuterol, as rescue medications. However, the use of short-acting β2-adrenergic receptor agonists alone does not address the underlying inflammation, leaving patients at risk of severe exacerbations which can lead to decreased quality of life, hospitalization, and frequent use of oral corticosteroids. Additionally, risks of adverse health outcomes are associated with 1-3 short courses of oral corticosteroid treatment of exacerbation, including type 2 diabetes, depression/anxiety, renal impairment, cataracts, cardiovascular disease, pneumonia, and fractures. In January 2023, AstraZeneca's official website announced that Airsupra (albuterol/budesonide, PT027), the first and only rescue medication approved in the United States for as-needed use to reduce the risk of asthma exacerbation, has been authorized in the U.S. for as-needed treatment or prevention of bronchospasm, and to lower the risk of asthma exacerbation in patients aged 18 years and older. The approved Airsupra is a pressurized metered-dose inhaler (pMDI) and fixed-dose combination rescue medication, co-developed by AstraZeneca and Avillion, containing the short-acting β2-adrenergic agonist albuterol and the anti-inflammatory inhaled corticosteroid budesonide. Based on the results of a clinical study (MANDALA trial) published in the New England Journal of Medicine in May 2022, the combination therapy of Airsupra was shown to significantly reduce the risk of severe exacerbations in patients with moderate to severe asthma when used as-needed as a rescue medication, compared to the use of albuterol alone. Importantly, at the approved dose (90 mcg albuterol/80 mcg budesonide), Airsupra significantly reduced the average annualized total systemic corticosteroid exposure, a key secondary endpoint, compared to albuterol. According to statistics from the Synapse database, there are 1,565 investigational drugs and 148 marketed drugs globally for the treatment of asthma. The β2-adrenergic receptors and glucocorticoid receptors mentioned in this article are the most important therapeutic targets for asthma. In addition, other popular targets include the H1 histamine receptor, acetylcholine receptor, IgE, CysLT, IL-5, etc. Among them, monoclonal antibody drugs targeting IgE (Omalizumab), IL-5 (Mepolizumab, Reslizumab), and TSLP (Tezepelumab) have been approved and launched on the market in recent years. β2AR and Compound Asthma MedicationThe β2 adrenergic receptor (β2AR) is one of the most classic members of the GPCR family. Due to its extensive distribution in lung tissues, it plays a critical role in the pathogenesis and treatment of asthma. Activation of β2 adrenergic receptors results in an increase in intracellular cAMP levels, which in turn activates protein kinase A. The activation of protein kinase A leads to relaxation of smooth muscles, particularly the relaxation of bronchial smooth muscles. This effect aids in the dilation of airways, reduction of respiratory resistance, and improvement of ventilation capacity. In asthma patients, the bronchial smooth muscles are more sensitive to various stimuli, causing airway constriction. Activation of β2 adrenergic receptors helps to mitigate this airway constriction and improve breathing by promoting the relaxation of the bronchial smooth muscles. Therefore, β2 adrenergic receptor agonists are commonly used medications for the treatment of asthma. β2 agonists are divided into two categories: short-acting and long-acting. Short-acting β2 agonists are primarily used for emergency relief to quickly alleviate acute asthma symptoms. Long-acting β2 agonists are usually used for the long-term control of asthma and can help prevent the occurrence of symptoms. More than half of the drugs that target β2 adrenergic receptors worldwide, either in clinical research or approved for clinical use, are related to the treatment of asthma. This includes asthma, chronic obstructive pulmonary disease (COPD), mild asthma, allergic asthma, and more. In addition to the development of non-selective or selective agonists targeting β2 adrenergic receptors alone, β2 adrenergic receptors are often paired with other asthma targets for the development of combination formulations. Common combinations include those with GR (glucocorticoid receptors), mAChRs (muscarinic acetylcholine receptors), H1R (histamine receptor 1), β1AR (beta-1 adrenergic receptors), DRDs (dopamine receptors), and others. Combination asthma medications are designed to control asthma symptoms more comprehensively through different mechanisms of action. Compared to single-component β2 agonists, combination asthma medications better meet patients' needs and offer a more comprehensive treatment effect. Inhaled corticosteroids: Inhaled corticosteroids (such as fluticasone, budesonide, etc.) are commonly used drugs for controlling asthma inflammation. They can reduce the inflammatory response within the airways and decrease mucus production, thereby helping to alleviate airway obstruction. Leukotriene modifiers: For example, montelukast is a leukotriene modifier that can block the actions of leukotrienes, reducing the inflammatory response and lowering airway hyperresponsiveness. Some combination asthma medications combine these different types of drugs to simultaneously relieve asthma symptoms through multiple pathways. Such combinations can enhance therapeutic efficacy to some extent, reduce the frequency of medication use, and improve patient compliance.

12 Jul 2022

·medcitynews.com

Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma

The available treatments for eosinophilic asthma come with a wide range of side effect risks. Areteia Therapeutics is developing an oral therapy designed to match the blockbuster biologic drugs that treat this severe form asthma, but with a potentially better safety profile. On Tuesday, the new company unveiled its approach along with up to $350 million in financial commitments to support pivotal tests of its experimental medicine. Like other forms of asthma, eosinophilic asthma causes inflamed airways that are blocked by mucus, making it difficult to breathe. But eosinophilic asthma stems from a type of white blood cell called an eosinophil. In high levels, eosinophils cause inflammation in the airways. Areteia’s lead drug candidate is dexpramipexole, a first-in-class small molecule designed to block the maturation and release of eosinophils in the bone marrow, where these cells are produced. In a placebo-controlled Phase 2 test enrolling patients with moderate-to-severe eosinophilic asthma, company said that treatment with its drug led to significant, dose-dependent reduction in eosinophil levels in the blood at each of the three doses tested. Furthermore, the once-daily pill was well tolerated by patients and no serious adverse effects were reported. With the new capital, Areteia plans to advance to Phase 3 testing. Success there could bring redemption for a drug that previously fell short in amyotrophic lateral sclerosis (ALS). Dexpramipexole comes from the labs of Pittsburgh-based Knopp Biosciences. A decade ago, that privately held drug discovery company was developing dexpramipexole for ALS in a research partnership with Biogen. In 2013, Biogen reported that the drug failed its Phase 3 clinical trial. Under Knopp, the drug continued clinical development in eosinophilic asthma. The first line of eosinophilic asthma treatments are typically inhaled steroids. If the symptoms are severe, oral steroids offer another option. But long-term use of these drugs raises the risks of developing osteoporosis, weight gain and diabetes. Injectable biologic drugs offer yet another treatment option. These antibody drugs are designed to block interleukin 5, a signaling protein that plays a key role in the maturation of eosinophils. These drugs can also cause hypersensitivity reactions and raise the risk of infections, but that hasn’t stopped them from becoming big sellers. AstraZeneca’s Fasenra and GSK’s Nucala accounted for $1.2 billion and £1.14 billion (about $1.15 billion) respectively in 2021 revenue, according to company financial reports. Teva Pharmaceutical Industries markets Cinqair for eosinophilic asthma; that company’s annual report does not break out sales for individual products. Areteia was created by Knopp and Population Health Partners, a private equity firm that forms new companies around late-stage drug candidates with the potential to address prevalent diseases. If dexpramipexole can win regulatory approval as the first oral drug for eosinophilic asthma, the company said that it could become an alternative to biologic drugs with the potential of also finding use as an earlier line of therapy. The Series A round of funding announced Tuesday was led by Bain Capital Life Sciences. With the financing, dexpramipexole transfers from Knopp to Areteia. Other investors include Access Biotechnology, GV, Arch Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners. Photo credit: Jackie Niam, Getty Images

CollaborateSmall molecular drugAntibodyFirst in ClassFinancial Statement

08 Jun 2022

·www.prnewswire.com

Severe Asthma Market to Progress Upto USD 7 Billion by 2032 | DelveInsight

The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. LAS VEGAS, June 8, 2022 /PRNewswire/ -- DelveInsight's Severe Asthma Market Insights report proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). Some of the salient features from the Severe Asthma Market Report : As per DelveInsight's analysis, the Severe Asthma market size in the 7MM was valued at almost USD 6 Billion in 2021 and is anticipated to grow at a CAGR of 5% for the study period (2019-2032). Key Severe Asthma companies such as GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others are reported to bring a significant shift in the Severe Asthma market. The Severe Asthma emerging therapies that are expected to launch in the forecast period include GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, CBP-201, PRS-060/AZD1402, BSI-045B, AVTX-002, and others. As per DelveInsight, the United States has the highest percentage of Severe Asthma patients pool among the 7MM. In addition to that, according to DelveInsight's analysts among the EU5 countries, the United Kingdom has the largest patient population of Severe Asthma, whereas Spain had the lowest patient population of Severe Asthma. Assessments as per DelveInsight's analysts indicate that Asthma diagnosed prevalence was more in adults than in pediatrics in the 7MM. The development of well-designed, randomized, controlled non-crossover trials with the potential benefits for Severe Asthma patients will drive the market growth in the forecast period. Also, approval and entry of new drugs will change the Severe Asthma market dynamics in the future. For further information on market impact by therapies, download the Severe Asthma market sample @ Severe Asthma Therapeutics Market Scenario Severe Asthma Overview Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodelling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic Asthma symptoms include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate. Asthma classification can be broadly done into intermittent or persistent. Here, Persistent asthma is further sub-divided based on severity into mild, moderate, and severe. Severe Asthma occurs due to various genetic, environmental, and psychological factors as well as respiratory infections. Severe Asthma symptoms appear often in the nighttime with a persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment. Based upon response to treatment, Severe Asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma. Severe Asthma Epidemiology Segmentation As per the assessment of DelveInsight, the total diagnosed prevalent (adult + pediatric) cases of Asthma in the 7MM was observed to be approximately 54 million cases in 2021. These cases are expected to increase by 2032. As per DelveInsight's estimates, among 7MM, the United States had the highest diagnosed cases of adult Asthma with almost 20 million cases in 2021. The Severe Asthma Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into Total Diagnosed Prevalent (adult + pediatric) Cases of Asthma Severity-specific Diagnosed Prevalent Cases of Asthma Type-specific Diagnosed Prevalent Cases of Severe Asthma Learn more about the Severe Asthma Population Trends for the 7 MM by downloading @ Severe Asthma Epidemiology Forecast Report Severe Asthma Market Outlook The fundamental goal of Asthma therapy is to minimize airway inflammation and also reduce the Asthma symptoms that come with it. To limit the likelihood of exacerbation, guidelines-based care focuses on illness severity and selecting the right medicinal therapy. Inhaled corticosteroids are the most common chronic asthma treatment, but quick-relief (reliever) or rescue medications are frequently used to reduce acute Asthma symptoms. Short-acting beta-agonists (SABAs) relieve airway bronchoconstriction quickly and are indicated as a symptom-relieving rescue drug. If asthma still isn't under control, long-acting beta 2 agonists (LABA), montelukast, or theophylline are added. If Asthma symptoms and flare-ups persist, oral corticosteroids are prescribed. There are currently six US FDA approved monoclonal antibodies for add-on biological Severe Asthma treatment. They include Cinqair (reslizumab) Teva Pharmaceutical, Dupixent (dupilumab) Sanofi, and Regeneron, Fasenra (benralizumab) AstraZeneca/Kyowa Kirin, Tezspire (tezepelumab) AstraZeneca and Amgen, Nucala (mepolizumab) GlaxoSmithKline, and Xolair (omalizumab) Novartis/Genentech. Several new severe asthma therapeutic options are currently being developed. The key assets include GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI (budesonide-glycopyrrolate-formoterol inhalation)) by AstraZeneca, and PT027 (BDA MDI/Budesonide/albuterol sulfate metered-dose inhaler) by AstraZeneca and Bond Avillion. They are in the late stage of development and are expected to launch in the forecasted period (2022-2032). Several other companies are also developing drugs for Severe Asthma treatment including Novartis (CSJ117), 4D pharma (MRx-4DP0004), Roche (RG6173), Pieris Pharma, and AstraZeneca (PRS-060/AZD1402), Biosion (BSI-045B), among others. Discover more about therapy set to grab substantial Severe Asthma market share @ Severe Asthma Market Landscape Severe Asthma Pipeline Therapies and Key Companies GSK3511294 (Depemokimab): GlaxoSmithKline PT010: AstraZeneca PT027: AstraZeneca and Avillion CSJ117: Novartis MRx-4DP0004: 4D pharma RG6173: Roche PRS-060/AZD1402: Pieris Pharma and AstraZeneca BSI-045B: Biosion AVTX-002: Avalo Therapeutics To know about more pipeline therapies covered in the report, visit @ Severe Asthma Pipeline Analysis, Clinical Trials, and Emerging Therapies Severe Asthma Market Dynamics Severe Asthma market growth in the coming years is dependent on several factors such as an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. Also, the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for patients will drive the Severe Asthma market growth in the forecast period. In addition to that, approvals and entry of new drugs will change the Severe Asthma market dynamics in the future. Several pharmaceutical giants are investigating drugs for Severe Asthma treatment with an improved diagnostic approach leading to a rise in the Severe Asthma market in the coming years. On the other hand, a lack of effective specific treatments in non-eosinophilic asthma (NEA) can represent an orphan asthma endotype serving as a drawback in the Severe Asthma market growth. Other factors such as a high cost of treatment, limitations in diagnosis, incorrect inhaler techniques, and poor adherence to treatment can all be considered as potential barriers to the rise of the Severe Asthma market. Know which therapy is expected to score the touchdown first @ Severe Asthma Market Landscape and Forecast Scope of the Severe Asthma Market Report Study Period: 2019-2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, Amgen, Avalo Therapeutics, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, and many others. Key Severe Asthma Pipeline Therapies: GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060/AZD1402, BSI-045B, AVTX-002, and others Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and emerging therapies Severe Asthma Market Dynamics: Severe Asthma market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Severe Asthma Market Access and Reimbursement Request for a Webex demo of the report @ Severe Asthma Therapeutics Market Table of Contents Get in touch with our Business executive @ Severe Asthma Market Landscape Analysis Related Reports Asthma Market DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Allergic Asthma due to Dermatophagoides Farinae Market DelveInsight's "Allergic Asthma due to Dermatophagoides Farinae- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Allergic Asthma due to Dermatophagoides Farinae, historical and forecasted epidemiology, current Allergic Asthma due to Dermatophagoides Farinae treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Eosinophilic Asthma Market DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Asthma Epidemiology DelveInsight's 'Asthma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Pulse Oximeters Market DelveInsight's 'Pulse Oximeters Market Insights, Competitive Landscape and Market Forecast - 2027' report deliver an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers, and key companies involved like Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others. Cough Assist Devices Market "DelveInsight's 'Cough Assist Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as Koninklijke Philips N.V, Percussionaire Corp., Emerson, Hill Rom, Dima Italia SRL, and many more. Cough in Idiopathic Pulmonary Fibrosis Market DelveInsight's 'Cough in Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market Forecast– 2032' report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the Cough in IPF market trends, market drivers & barriers, unmet needs and key companies involved such as Algernon Pharmaceuticals, Trevi Therapeutics, Nerre Therapeutics, and others. Chronic Obstructive Pulmonary Disease Market DelveInsight's 'Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032' report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends, market drivers & barriers, unmet needs and key companies involved such as AstraZeneca, Amgen, Circassia Pharmaceuticals Inc, Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Genentech, GlaxoSmithKline, Theravance, Innoviva, Inmunotek, Mereo BioPharma, Novartis Pharmaceuticals, and several others. Asthma Diagnostic Devices Market "DelveInsight's 'Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers, and key companies involved such as Medline Industries, Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Nihon Kohden Corporation, Vitalograph, Circassia Limited, Intermedical (UK) Limited, and several others. Chronic Obstructive Pulmonary Disease Treatment Devices Market "DelveInsight's 'Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease Treatment Devices and the historical and forecasted Chronic Obstructive Pulmonary Disease Treatment Devices market trends, drivers, barriers and key companies involved such as GlaxoSmithKline plc, Novartis AG, Merck & Co., Koninklijke Philips N.V, AstraZeneca, 3M, GF HEALTH PRODUCTS, Sunovion Pharmaceuticals Inc, Smiths Medical, Baxter, and others. Interested to know more about the breakthrough happenings? Take a look at the posts below Asthma: Rising Prevalence And The Key Challenges In The Management Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect With Us at LinkedIn | Facebook | Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 SOURCE DelveInsight Business Research, LLP

Antibody

100 Deals associated with Reslizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D08985	Reslizumab	R03DX08	DB06602

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Eosinophilia	European Union	Teva Pharmaceuticals Europe BV	15 Aug 2016
Pulmonary Eosinophilia	Iceland	Teva Pharmaceuticals Europe BV	15 Aug 2016
Pulmonary Eosinophilia	Liechtenstein	Teva Pharmaceuticals Europe BV	15 Aug 2016
Pulmonary Eosinophilia	Norway	Teva Pharmaceuticals Europe BV	15 Aug 2016
Eosinophilic Asthma	Canada	Teva Canada Ltd.	20 Jul 2016
Asthma	United States	Teva Respiratory LLC	23 Mar 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis	Phase 3	Canada	Teva Pharmaceuticals USA, Inc.	01 Oct 2015
Severe persistent asthma	Phase 3	Canada	Teva Pharmaceuticals USA, Inc.	01 Oct 2015
Eosinophilic Esophagitis	Phase 3	United States	Cephalon, Inc.	01 Jul 2008
Eosinophilic Esophagitis	Phase 3	Canada	Cephalon, Inc.	01 Jul 2008
Churg-Strauss Syndrome	Phase 2	United States	Teva Pharmaceuticals USA, Inc.	12 Sep 2017
Severe asthma	Phase 2	Spain	Teva Pharmaceuticals USA, Inc.	20 Apr 2017
airway disease	Phase 2	United States	Cephalon, Inc.	01 Apr 2008
airway disease	Phase 2	Canada	Cephalon, Inc.	01 Apr 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2022	Not Applicable	Pulmonary Eosinophilia interleukin-5 (IL-5)	24	Reslizumab	tpuxllhlnc(pmpvnxngzq) = lpbblwmvrn btjfnpqltl (zqsbjxcwyg )	Positive	04 Sep 2022
ERS2022	Not Applicable	Asthma	-	reslizumab	abfkuzsmuj(ndyjtpzdsf) = dviyqvevgt tmtdrmfawd (kdpgvptjwp )	Positive	04 Sep 2022
ERS2022	Not Applicable	Asthma	-	reslizumab	abfkuzsmuj(ndyjtpzdsf) = aojyqjlttx tmtdrmfawd (kdpgvptjwp )	Positive	04 Sep 2022
NCT02947945 (Pubmed \| Ann Allergy Asthma Immunol) Manual	Phase 2	Churg-Strauss Syndrome	10	reslizumab	kbwoxoohkb(yylkacwdyx) = yzltumvszy poxkomqxpd (blfbxeaywc )	Positive	01 Jun 2021
ERS2019	Not Applicable	Churg-Strauss Syndrome	9	Reslizumab	dtiiupwxpq(tyyllevmsw) = qidtrukxtb isjjtqblsi (sluumxlrek, 9.1)	-	28 Sep 2019
ERS2019	Not Applicable	Pulmonary Eosinophilia	477	Reslizumab	bhyphjuqmv(fvwdgxmkxl) = zwncrfprwp rnoonwoglq (sphvyxjmyt ) View more	-	28 Sep 2019
ERS2019	Not Applicable	Pulmonary Eosinophilia	477	Placebo	dkchghzgrr(eggicooirv) = fgcxvglcsb otbhalckkz (ibgjgqxerc )	-	28 Sep 2019
NCT03052725 (CTgov)	Phase 3	Eosinophilic Asthma	391	reslizumab	scyxksaura(rzivwgyrex) = ddifncplvk vfbregqzqf (ltvnlcqxjn, pvrffmhrcy - hmjymuxaiq) View more	-	21 Mar 2019
AAAAI2019	Phase 3	Eosinophilia, Familial blood Eosinophil (EOS)	477	IV Reslizumab 3mg/kg	yvnibxnxtu(bjqnwxiocr) = Clinicians should be aware of some patients (<1%) with delayed EOS suppression, and might consider re-measuring blood EOS levels in apparent reslizumab non-responders zohkjpapoz (jtrhyiovfm )	Negative	01 Feb 2019
AAAAI2019	Phase 3	Eosinophilic Asthma	953	Reslizumab 3mg/kg Q4W	izdqrmpezm(tsprigsrbj) = nkykbrdrjb sbuhtqpzlf (tmrxsavzkp )	-	01 Feb 2019
AAAAI2019	Phase 3	Eosinophilic Asthma	953	Placebo	izdqrmpezm(tsprigsrbj) = nyqurisvva sbuhtqpzlf (tmrxsavzkp )	-	01 Feb 2019
AAAAI2019	Not Applicable	fractional excretion of nitric oxide (FENO)	5	Reslizumab	lkekpdfpkh(lhjkijdkru) = boaprsnqsn ginacgjtvl (ltzyxzbopy )	-	01 Feb 2019
AAAAI2018	Not Applicable	blood eosinophils	-	Reslizumab 3mg/kg	chovjhwvch(ujcnxponge) = hkwmpiidyi zhlifioonb (zhvbsrawnc, 55 - 161)	-	01 Feb 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis